

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/593,259
				Filing Date	July 26, 2007
				First Named Inventor	Jean P. Cornet
				Art Unit	1628
				Examiner Name	J. Cornet
Sheet	1	of	4	Attorney Docket Number	014.0005-US00

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-4,363,813	12-14-1982	Kawasaki et al.	
	2.	US-5,374,772	12-20-1994	Casson et al.	
	3.	US-6,248,790 B1	06-19-2001	Uckun et al.	
	4.	US-6,432,957 B1	08-13-2002	Kodoma et al.	
	5.	US-7,851,501	12-14-2010	Aydt et al.	
	6.	US-7,919,532	04-05-2011	Aydt et al.	
	7.	US-7,923,473	04-12-2011	Aydt et al.	
	8.	US-2003/0187306 A1	10-02-2003	Sinha et al.	
	9.	US-2005/0113416 A1	05-26-2006	Wang et al.	
	10.	US-2009/0030015	01-29-2009	Kranich et al.	
	11.	US-2011/0053939	03-03-2011	Aydt et al.	
	12.	US-2011/0142765	06-16-2011	Aydt et al.	
	13.	US-2011/0152291	06-23-2011	Aydt et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	14.	EP 0217204 A1	04-08-1987	Merck & Co.		
	15.	EP 0465122 A1	01-08-1992	Merck & Co.		
	16.	EP 0426468 B1	09-06-1995	Orion-Yhtymä Oy		
	17.	EP 0840606 B1	06-07-2000	Texas Biotechnology Corp.		
	18.	EP 0758243 B1	03-12-2003	Texas Biotechnology Corp.		
	19.	EP 1481669 A1	12-01-2004	Yamanouchi Pharma Co.		
	20.	EP 1577289 A1	09-21-2005	Revotar Biopharmaceuticals AG		
	21.	EP 1627644 A1	02-22-2006	Hisamitsu Pharmaceutical Co.		
	22.	JP 2003 055369 A	06-03-2003	Univ Nihon		Abstract
	23.	WO 97/01335	01-16-1997	Texas Biotechnology Corp.		
	24.	WO 99/029705 A3	06-17-1999	Glycomed Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>IDS Form PTO/SB/08: Substitute for form 1449A/PTO</p> <p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center"><i>(Use as many sheets as necessary)</i></p>				Complete if Known		
				Application Number		10/593,259
				Filing Date		July 26, 2007
				First Named Inventor		Jean P. Cornet
				Art Unit		1628
				Examiner Name		J. Cornet
Sheet	2	of	4	Attorney Docket Number		014.0005-US00

FOREIGN PATENT DOCUMENTS						
	25.	WO 99/29706 A2	06-17-1999	Glycomed Inc.		
	26.	WO 99/29706 A3	06-17-1999	Glycomed Inc.		
	27.	WO 00/33836 A1	06-15-2000	Ontogen Corp.		
	28.	WO 03/097658 A2	11-27-2003	Glycotech Inc.		
	29.	WO 03/097658 A3	11-27-2003	Glycotech Inc.		
	30.	WO 2005/090284 A1	09-29-2005	Revotar Biopharmaceuticals AG		
	31.	WO 2007/039111 A3	04-12-2007	Revotar Biopharmaceuticals AG		
	32.	WO 2007/039112 A1	04-12-2007	Revotar Biopharmaceuticals AG		
	33.	WO 2007/039113 A1	04-12-2007	Revotar Biopharmaceuticals AG		
	34.	WO 2007/039114 A1	04-12-2007	Revotar Biopharmaceuticals AG		

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation ⁶
	35.	R.P. MCEVER, "8 Interactions of Selectins with PSGL-I and Other Ligands," Ernst Schering Res. Found. Workshop 44:137-147 (2004).		
	36.	G. CONSTANTIN, "PSGL-I as a Novel Therapeutic Target," Drug News Perspect 17(9):579-586 (November 2004).		
	37.	OKAZAKI et al., "Enhancement of Metastatic Activity of Colon Cancer as influenced by Expression of Cell Surface Antigens," Journal of Surgical Research 78(JR985298):78-84 (September 22, 1997).		
	38.	A.M. MÜLLER et al., "Heterogeneous expression of cell adhesion molecules by endothelial cells in ARDS," Journal of Pathology 198(2):270-275 (2002).		
	39.	R.P. MCEVER, "Selectin-carbohydrate interactions during inflammation and metastasis," Glycoconjugate Journal 14:585-591 (1997).		
	40.	R.P. MCEVER et al., "Perspectives Series: Cell Adhesion in Vascular Biology" "Role of PSGL-I Binding to Selectins in Leukocyte Recruitment," J. Clin. Invest., The American Society for Clinical Investigation, Inc. 100(3):485-492 (August 1997).		
	41.	A. DI STEFANO et al., "Upregulation of Adhesion Molecules in the Bronchial Mucosa of Subjects with Chronic Obstructive Bronchitis," Am. J. Respir. Crit. Care. Med. 149(3):803-810 (1994).		
	42.	S. TERAJIMA et al., "An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis," Arch. Dermatol. Res. 290:246-252 (1998).		
	43.	M. SPERANDIO et al., "Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?" Vascular Disease Prevention 1:185-195 (2004).		
	44.	C.A. LIPINSKI et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings," Advanced Drug Delivery Reviews, 23:3-25 (1997).		
	45.	H. ULBRICH et al., "Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease," Trends in Pharmacological Sciences 24(12):640-647 (2003).		
	46.	S.J. ROMANO, "Selectin Antagonists, Therapeutic Potential in Asthma and COPD," Treat. Respir. Med. 4(2):85-94 (2005).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>IDS Form PTO/SB/08: Substitute for form 1449A/PTO</p> <p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center"><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/593,259
				Filing Date	July 26, 2007
				First Named Inventor	Jean P. Cornet
				Art Unit	1628
				Examiner Name	J. Cornet
Sheet	3	of	4	Attorney Docket Number	014.0005-US00

NONPATENT LITERATURE DOCUMENTS			
	47.	M.P. SCHÖN, "Inhibitors of selectin functions in the treatment of inflammatory skin disorders," Therapeutics and Clinical Risk Management 1(3):201-208 (2005).	
	48.	M. KUMAMOTO et al., "Effects of pH and Metal Ions on Antioxidative Activities of Catechins," Biosci. Biotechnol. Biochem. 64(1):126-132 (2001).	
	49.	E. SERGEDIENE et al., "Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure-activity relationships," FEBS Letters 462:392-396 (1999).	
	50.	K. SATOH et al., "Copper, but not Iron, Enhances Apoptosis-Inducing Activity of Antioxidants," Anticancer Research 17:2487-2490 (1997).	
	51.	N. SAKUGUCHI et al., "Reactive Oxygen Species and Intracellular Ca ²⁺ , Common Signals for Apoptosis Induced by Gallic Acid," Biochemical Pharmacology 55:1973-1981 (1998).	
	52.	D. BOCK et al., "Innovative Strategy in Inflammatory Diseases," New Drugs D04(28):28-30 (2003).	
	53.	E. AYDT et al., "Development of Synthetic Pan-Selectin Antagonists: A New Treatment Strategy for Chronic Inflammation in Asthma," Pathobiology 70:297-301 (2002-2003).	
	54.	N.V. BOVIN, "Neoglycoconjugates: trade and art," Biochem. Soc. Symp. 69:143-160 (2002).	
	55.	N.V. BOVIN, "Polyacrylamide-based glycoconjugates as tools in glycobiology," Glycoconjugate Journal 15:431-446 (1998).	
	56.	T.V. POCHUEHUEVA et al., "P-Selectin Blocking Potency of Multimeric Tyrosine Sulfates In Vitro and In Vivo," Bioorganic & Medicinal Chemistry Letters 13(10):1709-1712 (2003).	
	57.	G. WEITZ-SCHMIDT et al., "An E-Selectin Binding Assay Based on a Polyacrylamide-Type Glycoconjugate," Analytical Biochemistry 238:184-190 (1996).	
	58.	T. NOMOTO et al., "Preparation of hydroxybenzamide derivatives as prevention and treatment agents for bone diseases," Chemical Abstracts + Indexes, American Chemical Society 125(13):XP002047512 (September 23, 1996).	
	59.	R. YAMAZAKI et al., "Diarylheptanoids suppress expression of leukocyte adhesion molecules on human vascular endothelial cells," European Journal of Pharmacology 404(3):375-385, XP009062460 (September 22, 2000).	
	60.	C.C.M. APPELDOORN et al., "Gallic Acid Antagonizes P-Selectin-Mediated Platelet-Leukocyte Interactions, Implications for the French Paradox," Circulation 111:106-112 (January 2005).	
	61.	N. KAILA et al., "Quinic Acid Derivatives as Sialyl Lewis ^x -Mimicking Selectin Inhibitors: Design, Synthesis, and Crystal Structure in Complex with E-Selectin," J. Med. Chem. 48:4346-4357 (2005).	
	62.	D.H. SLEE et al., "Development of Potent Non-Carbohydrate Imidazole-Based Small Molecule Selectin Inhibitors with Antiinflammatory Activity," J. Med. Chem. 44:2094-2107 (2001).	
	63.	P.T. MANNISTO et al., "Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors," PHARMACOLOGICAL REVIEWS, The American Society for Pharmacology and Experimental Therapeutics 51(4):593-628 (1999).	
	64.	J. AXELROD et al., "Enzymatic O-Methylation of Epinephrine and Other Catechols," J. Biol. Chem. 223(3):702-705 (1958).	
	65.	N. HARAMAKI et al., "Role of Ascorbate in Protection by Nitecapone Against Cardiac Ischemia - Reperfusion Injury," Biochemical Pharmacology 50(6):839-843 (1995).	
	66.	E. NISSINEN et al., "The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats," J. Neural. Transm. 112:1213-1221 (2005).	
	67.	Y.J. SUZUKI et al., "Antioxidant Properties of Nitecapone (OR-462)," Free Radical Biology & Medicine 13:517-525 (1992).	
	68.	L. MARCOCCI et al., "Nitecapone: A Nitric Oxide Radical Scavenger," Biochemistry and Molecular Biology International 34(3):531-541 (October 1994).	
	69.	T. HELKAMAA et al., "Entacapone protects from angiotensin II-induced inflammation and renal injury," Journal of Hypertension 21:2353-2363 (2003).	
	70.	M. FRIEDRICH et al., "Pan-selectin antagonism improves psoriasis manifestation in mice and man," Arch Dermatol Res. 297:345-351, XP002370636 (2006).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>IDS Form PTO/SB/08: Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				<i>Application Number</i>	10/593,259
				<i>Filing Date</i>	July 26, 2007
				<i>First Named Inventor</i>	Jean P. Cornet
				<i>Art Unit</i>	1628
				<i>Examiner Name</i>	J. Cornet
Sheet	4	of	4	<i>Attorney Docket Number</i>	014.0005-US00

NONPATENT LITERATURE DOCUMENTS			
	71.	Van De Waterbeemd H et al., "Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics," J. Med. Chem. 44(9):1313-1333 (2001).	
	72.	Harvey et al., "The results of five coded compounds: genistein, metaproterenol, rotenone, <i>p</i> -anisidine and resorcinol tested in the pH 6.7 Syrian hamster embryo cell morphological transformation assay," Mutagenesis 20(1):51-56 (2005).	
	73.	Nov. 16, 2009, Office Action in U.S. App. No. 12/067,389 (Examiner P. Zarek).	
	74.	July 30, 2010, Office Action in U.S. App. No. 12/067,389 (Examiner P. Zarek).	
	75.	July 30, 2010, Office Action in U.S. App. No. 12/066,757 (Examiner T. Thomas).	
	76.	Feb. 14, 2011, Office Action in U.S. App. No. 12/066,757 (Examiner T. Thomas).	
	77.	Jan. 8, 2010, Office Action in U.S. App. No. 12/067,341 (Examiner V. Rodriguez-Garcia).	
	78.	Nov. 18, 2009, Office Action in U.S. App. No. 12/067,059 (Examiner P. Zarek).	
	79.	July 29, 2010, Office Action in U.S. App. No. 12/067,059 (Examiner P. Zarek).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO Notes regarding this form:

- ¹ Applicant's unique citation designation number (optional).
 - ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
 - ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
 - ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
 - ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
 - ⁶ Applicant is to place a check mark here if English language Translation is attached.
- This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**